Can We Prevent or Delay Type 2 Diabetes? by Merita Emini Sadiku
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2012 Sadiku, licensee InTech. This is an open access chapter distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Can We Prevent or Delay Type 2 Diabetes? 
Merita Emini Sadiku 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/54872 
1. Introduction 
Type 2 diabetes results from the interaction between genetic predisposition, behavioral and 
environmental risk factors (1). There is strong evidence that modifiable risk factors such as 
obesity and physical inactivity are the main non-genetic determinants of the disease(2). New 
figures indicate that the number of people living with diabetes is expected to rise from 366 
million to 552 million by 2030, if no urgent action is taken (3).  
Impaired glucose tolerance (IGT) is an intermediate category between normal glucose 
tolerance and overt diabetes, and it can be identified by glucose tolerance test. Subjects with 
IGT have an increased risk of type 2 diabetes (4), and consequently many trials of 
interventions for the prevention of type 2 diabetes have focused on such individuals. By 
2025, the number of people with IGT is projected to increase to 418 million, or 8.1% of the 
adult population (5).  
Interventions to delay or even to prevent type 2 diabetes have a potential to improve the 
health of the population and reduce the burden of healthcare costs. The interventions 
assessed have been diverse and include pharmacological and lifestyle changes.  
Abnormal glucose tolerance is also a well-known risk factor of incident diabetes (6). The 
main known predictor of incident diabetes is the presence of insulin resistance. Direct 
measures of insulin sensitivity can be laborious, complicated, and expensive to be applicable 
for routine use in the general population as a screening tool. Markers like HOMA-IR index 
or 2-hour post-challenge glucose levels are being used to diagnose insulin resistance. 
IGT when compared to impaired fasting glucose (IFG) is a stronger risk factor in predicting 
the onset of diabetes (7). Diagnosing of IGT requires oral glucose tolerance test (OGTT), a 
test of high specificity (92%) but low sensitivity (52%) in the prediction of diabetes (8). The 
World Health Organization (WHO) criteria including either IFG (≥6.1 mmol/L and <7.0 
mmol/L and 2-h plasma glucose concentration <11.1 mmol/L during the oral glucose 
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tolerance test) or IGT test (<7.0 mmol/L and 2-h plasma glucose concentration ≥7.8 mmol/L 
and <11.1mmol/L) are used to diagnose people with IGT (9).  
The clinical characteristics associated with type 2 diabetes risk include obesity and 
overweight, age (the risk rises steadily from puberty into geriatric years), a history of 
gestational diabetes, polycystic ovary syndrome, a family history of type 2 diabetes, and 
membership in certain high-risk minority groups: African American, Hispanic, Native 
American, and Asian-Pacific Islanders (6). The ADA recommends screening youth and 
adults with multiple risk factors for type 2 diabetes; fasting plasma glucose is the preferred 
first-line test (10, 11). 
People with metabolic syndrome are at a high risk to develop diabetes and ischemic 
atherosclerotic diseases (7). Several studies have shown that metabolic syndrome is a strong 
predictor of incident diabetes (12-14). 
The Insulin Resistance Atherosclerosis Study (IRAS) assessed a series of risk factors and 
identified five significant risk factors for the development of type 2 diabetes including high 
plasminogen activator inhibitor 1 (PAI-1), hypertension (HTN), high triglycerides (TG), low 
high-density lipoprotein (HDL), and IGT. The incidence of type 2 diabetes increases with the 
increasing number of risk factors, 5% with 0 risk factors to 50% when all 5 risk factors are 
present (p<0.001) (15). 
Every year about 5%-10% of people with IGT will develop diabetes and acquire the disease 
burden related to its diagnosis symptoms, need for surveillance for chronic consequences 
and associated costs, and increased risk of several chronic diseases (16).  
The purpose of this article is to review available evidence on lifestyle and pharmacological 
intervention on the prevention or delay of the onset of type 2 diabetes and adapting these 
lessons from clinical trials to clinical practice. 
2. How we can prevent type 2 diabetes? 
The high economic and social costs of type 2 diabetes mellitus and its rising prevalence 
make a compelling case for its prevention (17). The most vulnerable groups to have diabetes 
are people with IFG and IGT and in the mean time they present the potent groups of 
preventing or delaying the progression to type 2 diabetes mellitus. These two groups are 
recognized as prediabetic states by the ADA (11). 
3. Non pharmacological intervention  
Four large prospective studies demonstrated that a treatment regimen using diet plus 
exercise reduces IGT progression to type 2 diabetes (18-21). Factor analysis showed that both 
insulin resistance and insulin secretion had a significant association with the development 
of diabetes, and lifestyle intervention was more effective in subjects with lower insulin 
resistance and higher insulin secretion (13).  
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3.1. Lifestyle trials - diet and physical activity 
Overweight, obesity and physical inactivity are the major risk factors for developing type 2 
diabetes mainly through insulin resistance. Therefore, interventions in  weight reduction 
were shown to enhance insulin sensitivity and improve glucose tolerance in nondiabetic and 
diabetic subjects.  
In the DaQing study, 577 subjects with IGT as defined by the WHO criteria were followed 
over 6 years. They were randomized into diet-only, exercise only, diet plus exercise groups, 
and a control group, which were associated with a 31% (p≤0.03), 46% (p≤0.0005) and 42% 
(p≤0.005) reduction in the risk of developing diabetes, respectively, when compared to the 
control group. Factor analysis showed that both insulin resistance and insulin secretion had 
a significant association with the development of diabetes, and lifestyle intervention was 
more effective in subjects with lower insulin resistance and higher insulin secretion 
(15,21,22). 
The Swedish Diabetes Prevention Study was the first individually randomized clinical trial, 
where 522 middle-aged overweight subjects (body mass index/BMI >25) with IGT were 
randomized to the control group or intervention group and followed over a mean of 3.2 
years. The intervention group received individual counseling regarding diet and exercise 
and lost 4.2±5.1 kg versus 0.8±3.7 kg in the control group, which translated to a 58% (p≤0.001) 
reduction in the risk of developing diabetes and was directly associated with changes in 
lifestyle (18,23). 
The Diabetes Prevention Program (DPP) study was a double-blind randomized controlled 
trial (RCT) involving a larger number of subjects, 3234 with IGT or IFG with BMI >24 kg/m2 
(>22 in Asian population) followed over 2.8 years. They were randomized to standard 
lifestyle recommendations with placebo or with metformin or to an intensive program of 
lifestyle modifications (19). The incidence of developing diabetes was 4.8 cases versus 11 
cases per 100 person years for 3 years in the intensive lifestyle and placebo groups, 
respectively, which was a 58% lower incidence of developing diabetes in the intensive 
lifestyle group. In this study these changes were observed in all of the various ethnic and 
racial subgroups, and at least 50% of the lifestyle group had achieved the goal of >7% of 
weight reduction. 
The Look AHEAD trial, which, like DPP, demonstrated impressive weight loss at year 1, 
was also followed by significant weight regain over the subsequent 3 years despite 
continued intensive intervention and follow-up (24). 
In a recent community study in Finland, 2,797 high-risk individuals were enrolled in a 
diabetes prevention program designed to achieve 5–7% body weight loss. Only 
approximately one-third of participants were able to successfully decrease body weight by 
2.5% (25). 
From above mention studies it is obvious that successful weight reduction alone is not 
sufficient to prevent diabetes in a large percentage of individuals. The main issues is that it 
is difficult to maintain weight without an intervention program.  
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The key components of lifestyle interventions in clinical practice based on the studies 
analyzed by Burnet et al. (37) were as follows: the staff included were medical doctors, 
nurses, technicians, dietitians and physiotherapists. Trainings with patients were focused on 
nutrition, physical activity and behavioral self-management four times during the year in 
individualized sessions (in Diabetes Prevention Study) or small group counseling sessions 
weekly for one month, then monthly for three months (32). Physical activities were 
organized 2 times during the week as brisk walking (in Diabetes Prevention Program and 
Malmo Feasibility Study). Smokers were advised to stop or reduce smoking. It was a useful 
follow up session every 2 months with phone calls to patients between visits. In DPS study, 
if weight goal was not achieved in 6 to 12 months, a very low calorie diet was considered. 
As for social support, spouses were invited to join sessions. 
The overall goal for diabetes prevention is to reach and maintain an active, healthy weight 
with a tendency toward a hypocaloric diet. Evidence supports limiting total calories and fat 
(25% of caloric intake) and increasing dietary fiber (20 to 30 g/day). Essential skills include 
understanding portion sizes and reading food labels (37). 
4. Pharmacological interventions  
Weight regain is a characteristic feature of most weight reduction programs, irrespective of 
the type of dietary intervention and similarly, weight loss achieved with pharmacological 
intervention is associated with major weight regain once medication is discontinued.  
As shown above, lifestyle modification is the best strategy to prevent the progression of 
metabolic risk factors and to prevent cardiovascular events and the onset of diabetes. 
However, pharmacological trials have shown important results. 
4.1. Metformin 
Metformin (MF) 850 mg was used in one arm of the DPP study along with standard lifestyle 
recommendations. Subjects in this study had a decrease in their calorie intake by a mean of 
296±23 kcal compared to 249±27 kcal in the placebo group; their average fat intake decreased 
by 0.8±0.2% in both the MF and the placebo group (p=NS).  
The DPP demonstrated a 31% reduction in IGT conversion to type 2 diabetes in subjects 
receiving metformin, 850 mg twice daily (15,21). 
4.2. α-Glucosidase inhibitors  
Both acarbose (STOP-NIDDM) (26) and voglibose (27) have been shown to decrease 
conversion of IGT to type 2 diabetes. Although this preventive effect initially was believed 
to result from inhibition of carbohydrate absorption, α-glucosidases augment incretin 
hormone secretion; thus, enhanced b-cell function could, in part, explain their beneficial 
effects on glucose homeostasis (28). Subjects on acarbose were by 25% less likely to develop 
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diabetes compared to placebo at the end of 1 year, and this continued to the end of the 
study. The reduced risk was present even after adjusting for change in weight, age, sex, or 
BMI (p=0.0063) (26). 
4.3. Thiazolidinediones 
Thiazolidinediones (TZD) are insulin sensitizers that act by facilitating glucose transport 
into the muscle and by acting on Perioxisome Proliferator Activated Receptor (PPAR)-γ 
receptors in the adipose cells to shift fat from visceral to less active subcutaneous fat 
compartment thus reducing insulin resistance. The TRIPOD was a single-center, placebo-
controlled randomized controlled trials, which enrolled Mexican-American women with 
prior gestational diabetes mellitus (GDM) randomized to either placebo or troglitazone 400 
mg/day. The mean annual incidence of diabetes was 5.4% in the troglitazone group versus 
12.1% in the placebo group (p=0.009), which was a >50% reduction with troglitazone use 
(29). Analysis done 8 months after troglitazone had been stopped showed that the mean 
annual incidence of diabetes was 21.2% and 3.1% in the placebo and troglitazone group, 
respectively. This indicated that the protection by the drug persisted even after it had been 
stopped. The study was continued in the same group of women using pioglitazone called 
the Pioglitazone In the Prevention of Diabetes (PIPOD) study and the results published 
indicated that the benefit in terms of β-cell function achieved with troglitazone was 
maintained with the use of pioglitazone, indicating that it could be a class effect (30). Also, a 
report appeared on diabetes reduction assessment in the Ramipril and Rosiglitazone 
medication (DREAM) trial (16). This trial reported only combined results for individuals 
with either IGT or IFG. Briefly, it was found that the ACE inhibitor ramipril did not 
significantly reduce the incidence of diabetes (hazard ratio 0.91, 0.80 to 1.03) but 
rosiglitazone, an oral diabetes drug, did (0.38, 0.33 to 0.44). 
In another study ACT NOW, pioglitazone (45 mg/day) decreased by 72% (P <0.00001) IGT 
conversion to type 2 diabetes (31). 
4.4. Orlistat 
Orlistat is another pharmacological agent used in the prevention of diabetes. Orlistat is a 
weight-reduction agent that inhibits the activity of intestinal lipase and thus decreases the 
amount of fat (triglycerides) absorbed. After 4 years' treatment, the cumulative incidence of 
diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 
37.3% (P = 0.0032). Exploratory analyses indicated that the preventive effect was explained 
by the difference in subjects with IGT. Mean weight loss after 4 years was significantly 
greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat 
recipients with impaired (5.7 kg) or normal glucose tolerance (NGT) (5.8 kg) at baseline. A 
second analysis in which the baseline weights of subjects who dropped out of the study was 
carried forward also demonstrated greater weight loss in the orlistat group (3.6 vs. 1.4 kg; P 
< 0.001)(32). 
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4.5. GLP-1 analogs 
Liraglutide and exenatide are GLP-1 receptor agonists that mimic the actions of GLP-1 and 
are resistant to dipeptidyl peptidase-4 degradation. GLP-1 analogs represent a logical 
therapeutic intervention for treatment of IGT. Moreover, the stimulatory effect of GLP-1 and 
GLP-1 analogs on insulin secretion is glucose dependent, minimizing risk for hypoglycemia 
(33). Once-daily liraglutide also reduces body weight and decreases IGT conversion to type 
2 diabetes in obese nondiabetic subjects (34). 
4.6. Angiotensin converting enzyme inhibitor (ACEI)/angiotensinogen receptor 
blocker (ARB) 
In addition to the beneficial effects on hypertension, the kidneys and the heart, both ACEI 
and ARBs have been shown to improve insulin sensitivity and glycemic control. Therapy 
with ACEI, like captopril and ramipril, and ARBs, like losartan and valsartan has been 
shown to reduce the incidence of new-onset diabetes anywhere by 14% to 34% (18). 
Although the exact mechanism how these agents reduce the incidence of diabetes is not 
known, it is well established that ACEI increases glucose uptake in skeletal muscle through 
increased synthesis of GLUT- 4 transporter protein secondary to up-regulation of insulin 
receptor substrate 1 (IRS 1) activity, enhanced bradykinin and nitric oxide (NO) activity (35). 
4.7. Statins 
The West of Scotland Coronary Prevention Study (WOSCOPS) examined the effect of 
pravastatin on cardiovascular (CV) events and observed that these pharmacological 
interventions were associated with a 30% reduction in the incidence of diabetes as 
secondary outcome (36). Therapeutic agents used to treat other coexisting conditions like 
hypertension and dyslipidemia with agents like ACEI/ARB/statins can also help with the 
prevention of diabetes and CV disease (15). 
5. Conclusions and recommendations 
From the trials discussed it was shown that both non pharmacological and pharmacological 
intervention can reduce the risk of type 2 diabetes in people with IGT, but lifestyle 
intervention seems to be more effective than pharmacological interventions. Lifestyle 
intervention, which aims to reduce obesity and increase physical activity, helps in 
addressing directly these risk factors. In the mean time lifestyle interventions incur fewer 
and less serious side effects than drug treatment. Like in pharmacological interventions, 
lifestyle interventions may not be permanent and advice on diet and exercise needs to be 
regularly reinforced by professional staff. For pharmacological interventions, adverse effects 
need to be fully understood to enable the potential harms and benefits to be assessed. 
In lifestyle intervention, clinicians should recommend behavior changes for asymptomatic 
patients at a high risk of diabetes such as IGT. High-risk patients can be identified through 
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clinical characteristics augmented with careful screening by fasting glucose. Although the 
diabetes prevention trials used intensive strategies for effecting lifestyle change, clinicians 
can translate key elements from those strategies into brief, office-based counseling on 
physical activity and dietary change. As it was proved by different trials in clinical practice, 
lifestyle changes should be made better through structured programs. These programs, 
proved to be successful in clinical practices from different countries, should emphasize goal 
setting, practice and motivational interviewing with patients, education and skills 
development, self-monitoring, behavior change (cognitive restructuring), physical activity, 
problem solving,  stress and stimulus control, the importance of social support, and the 
utilization of community resources. 
Multidisciplinary care teams consisting of nurses, clinicians, dietitians, psychologist 
physiotherapists and health educators may provide more intensive counseling and increase 
the motivation to continue and achieve the targets. Other forms of awareness rising as 
printed materials or if possible interactive computer programs in offices can reinforce 
counseling efforts. Implementing diabetes prevention will require significant changes for 
both patients and clinicians. Every health system that provide these special services need to 
educate clinicians in training and in practice about the potential benefits of diabetes 
prevention. Appropriate programs on the prevention or delay of type 2 diabetes have to be 
culturally adaptive for office-based counseling considering the better results planned to 
achieve. Besides office bases counseling with patients and family members, successful 
diabetes prevention efforts through lifestyle changes will likely require involvement broader 
societal entities such as schools, communities and workplaces. 
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